<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39380944</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1687-8639</ISSN><JournalIssue CitedMedium="Print"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Advances in virology</Title><ISOAbbreviation>Adv Virol</ISOAbbreviation></Journal><ArticleTitle>In Silico Design of a Trans-Amplifying RNA-Based Vaccine against SARS-CoV-2 Structural Proteins.</ArticleTitle><Pagination><StartPage>3418062</StartPage><MedlinePgn>3418062</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3418062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2024/3418062</ELocationID><Abstract><AbstractText>Nucleic acid-based vaccines allow scalable, rapid, and cell-free vaccine production in response to an emerging disease such as the current COVID-19 pandemic. Here, we objected to the design of a multiepitope mRNA vaccine against the structural proteins of SARS-CoV-2. Through an immunoinformatic approach, promising epitopes were predicted for the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. Fragments rich in overlapping epitopes were selected based on binding affinities with HLA classes I and II for the specific presentation to B and T lymphocytes. Two constructs were designed by fusing the fragments in different arrangements via GG linkers. Construct 1 showed better structural properties and interactions with toll-like receptor 2 (TLR-2), TLR-3, and TLR-4 during molecular docking and dynamic simulation. A 50S ribosomal L7/L12 adjuvant was added to its N-terminus to improve stability and immunogenicity. The final RNA sequence was used to design a trans-amplifying RNA (taRNA) vaccine in a split-vector system. It consists of two molecules: a nonreplicating RNA encoding a trans-acting replicase to amplify the second one, a trans-replicon (TR) RNA encoding the vaccine protein. Overall, the immune response simulation detected that activated B and T lymphocytes and increased memory cell formation. Macrophages and dendritic cells proliferated continuously, and IFN-<i>γ</i> and cytokines like IL-2 were released highly.</AbstractText><CopyrightInformation>Copyright © 2024 Fatemeh Nafian et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nafian</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0622-4086</Identifier><AffiliationInfo><Affiliation>Department of Medical Laboratory Sciences Faculty of Paramedics Tehran Medical Sciences Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soleymani</LastName><ForeName>Ghazal</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourmanouchehri</LastName><ForeName>Zahra</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0003-4289-6960</Identifier><AffiliationInfo><Affiliation>Department of Biology Technical University of Kaiserslautern, Kaiserslautern Technical University of Kaiserslautern, Kaiserslautern, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyanjam</LastName><ForeName>Mahnaz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Biology Faculty of Advanced Sciences and Technology Tehran Medical Sciences Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nafian</LastName><ForeName>Simin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Stem Cell and Regenerative Medicine National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohammadi</LastName><ForeName>Sayed Mohammad</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Biotechnology Faculty of Converging Sciences and Technologies Science and Research Branch Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeyroudi</LastName><ForeName>Hanie</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Biology Faculty of Advanced Sciences and Technology Tehran Medical Sciences Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berenji Jalaei</LastName><ForeName>Sharareh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry Faculty of Converging Sciences and Technologies Science and Research Branch Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabzpoushan</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Cellular and Molecular Biology Faculty of Advanced Sciences and Technology Tehran Medical Sciences Islamic Azad University, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Virol</MedlineTA><NlmUniqueID>101508613</NlmUniqueID><ISSNLinking>1687-8639</ISSNLinking></MedlineJournalInfo><CoiStatement>All authors declare that they have no conflicts of interest regarding the present study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380944</ArticleId><ArticleId IdType="pmc">PMC11459942</ArticleId><ArticleId IdType="doi">10.1155/2024/3418062</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Satarker S., Nampoothiri M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Archives of Medical Research . 2020;51(6):482–491. doi: 10.1016/j.arcmed.2020.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.05.012</ArticleId><ArticleId IdType="pmc">PMC7247499</ArticleId><ArticleId IdType="pubmed">32493627</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.-J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy, and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clinical Microbiology and Infection . 2022;28(2):202–221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Nafian F., Nafian S., Soleymani G., et al. Next-generation vaccines based on self-amplifying RNA. 2021.</Citation></Reference><Reference><Citation>Ballesteros-Briones M. C., Silva-Pilipich N., Herrador-Cañete G., Vanrell L., Smerdou C. A new generation of vaccines based on alphavirus self-amplifying RNA. Current opinion in virology . 2020;44:145–153. doi: 10.1016/j.coviro.2020.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2020.08.003</ArticleId><ArticleId IdType="pmc">PMC7474593</ArticleId><ArticleId IdType="pubmed">32898764</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S. The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET. Pathogens and Immunity . 2020;5(1):p. 342. doi: 10.20411/pai.v5i1.377.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v5i1.377</ArticleId><ArticleId IdType="pmc">PMC7608487</ArticleId><ArticleId IdType="pubmed">33154981</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera N. G., Morano N. C., Celikgil A., et al. Characterization of the SARS-CoV-2 S protein: biophysical, biochemical, structural, and antigenic analysis. ACS Omega . 2020;6(1):85–102. doi: 10.1021/acsomega.0c03512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.0c03512</ArticleId><ArticleId IdType="pmc">PMC7771249</ArticleId><ArticleId IdType="pubmed">33458462</ArticleId></ArticleIdList></Reference><Reference><Citation>Hossain M. G., Tang Yd, Akter S., Zheng C. Roles of the polybasic furin cleavage site of spike protein in SARS‐CoV‐2 replication, pathogenesis, and host immune responses and vaccination. Journal of Medical Virology . 2022;94(5):1815–1820. doi: 10.1002/jmv.27539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27539</ArticleId><ArticleId IdType="pubmed">34936124</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X. Domains and functions of spike protein in Sars-Cov-2 in the context of vaccine design. Viruses . 2021;13(1):p. 109. doi: 10.3390/v13010109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010109</ArticleId><ArticleId IdType="pmc">PMC7829931</ArticleId><ArticleId IdType="pubmed">33466921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumavath R., Barh D., Andrade B. S., et al. The spike of SARS-CoV-2: uniqueness and applications. Frontiers in Immunology . 2021;12 doi: 10.3389/fimmu.2021.663912.663912</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.663912</ArticleId><ArticleId IdType="pmc">PMC8297464</ArticleId><ArticleId IdType="pubmed">34305894</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik Y. A. Properties of coronavirus and SARS-CoV-2. Malaysian Journal of Pathology . 2020;42(1):3–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32342926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruch T. R., Machamer C. E. The coronavirus E protein: assembly and beyond. Viruses . 2012;4(3):363–382. doi: 10.3390/v4030363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v4030363</ArticleId><ArticleId IdType="pmc">PMC3347032</ArticleId><ArticleId IdType="pubmed">22590676</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S., Bhattacharyya D., Bhunia A. Host-membrane interacting interface of the SARS coronavirus envelope protein: immense functional potential of C-terminal domain. Biophysical Chemistry . 2020;266 doi: 10.1016/j.bpc.2020.106452.106452</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpc.2020.106452</ArticleId><ArticleId IdType="pmc">PMC7418743</ArticleId><ArticleId IdType="pubmed">32818817</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra R., Chandra Das N., Mukherjee S. Targeting human TLRs to combat COVID‐19: a solution? Journal of Medical Virology . 2021;93(2):615–617. doi: 10.1002/jmv.26387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26387</ArticleId><ArticleId IdType="pmc">PMC7436140</ArticleId><ArticleId IdType="pubmed">32749702</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS‐CoV‐2 spike glycoprotein with ACE‐2 receptor homologs and human TLRs. Journal of Medical Virology . 2020;92(10):2105–2113. doi: 10.1002/jmv.25987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25987</ArticleId><ArticleId IdType="pmc">PMC7267663</ArticleId><ArticleId IdType="pubmed">32383269</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Das N. C., Patra R., Mukherjee S. In silico analyses on the comparative sensing of SARS‐CoV‐2 mRNA by the intracellular TLRs of humans. Journal of Medical Virology . 2021;93(4):2476–2486. doi: 10.1002/jmv.26776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26776</ArticleId><ArticleId IdType="pubmed">33404091</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Dong X., Ma R., et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nature Communications . 2020;11(1):p. 3810. doi: 10.1038/s41467-020-17665-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S. Toll-like receptor 4 in COVID-19: friend or foe? Future Virology . 2022;17:415–417. doi: 10.2217/fvl-2021-0249.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl-2021-0249</ArticleId><ArticleId IdType="pmc">PMC9017673</ArticleId><ArticleId IdType="pubmed">35462619</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Mukherjee G., Mukherjee S. Chemotherapy vs. Immunotherapy in combating nCOVID19: an update. Human Immunology . 2021;82(9):649–658. doi: 10.1016/j.humimm.2021.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2021.05.001</ArticleId><ArticleId IdType="pmc">PMC8130497</ArticleId><ArticleId IdType="pubmed">34020832</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zeng G., Pan H., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases . 2021;21(2):181–192. doi: 10.1016/s1473-3099(20)30843-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(20)30843-4</ArticleId><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Hu Y., Xu M., et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases . 2021;21(6):803–812. doi: 10.1016/s1473-3099(20)30987-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1473-3099(20)30987-7</ArticleId><ArticleId IdType="pmc">PMC7906628</ArticleId><ArticleId IdType="pubmed">33548194</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C., Albert G., Cho I., et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. New England Journal of Medicine . 2020;383(24):2320–2332. doi: 10.1056/nejmoa2026920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2026920</ArticleId><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S. A. C., Madhi S. A., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet . 2021;397(10269):99–111. doi: 10.1016/s0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Self W. H., Tenforde M. W., Rhoads J. P., et al. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson and Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March-August 2021. MMWR. Morbidity and Mortality Weekly Report . 2021;70(38):1337–1343. doi: 10.15585/mmwr.mm7038e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7038e1</ArticleId><ArticleId IdType="pmc">PMC8459899</ArticleId><ArticleId IdType="pubmed">34555004</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D. Y., Dolzhikova I. V., Zubkova O. V., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet . 2020;396(10255):887–897. doi: 10.1016/s0140-6736(20)31866-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Agoramoorthy G. India’s cost-effective COVID-19 vaccine development initiatives. Vaccine . 2020;38(50):7883–7884. doi: 10.1016/j.vaccine.2020.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.10.056</ArticleId><ArticleId IdType="pmc">PMC7574682</ArticleId><ArticleId IdType="pubmed">33129610</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F. P., Thomas S. J., Kitchin N., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine . 2020;383(27):2603–2615. doi: 10.1056/nejmoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson L. A., Anderson E. J., Rouphael N. G., et al. An mRNA vaccine against SARS-CoV-2—preliminary report. New England Journal of Medicine . 2020;383(20):1920–1931. doi: 10.1056/nejmoa2022483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman A., Martin M. J., Orchard S., et al. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Research . 2021;49(D1):480–489. doi: 10.1093/nar/gkaa1100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1100</ArticleId><ArticleId IdType="pmc">PMC7778908</ArticleId><ArticleId IdType="pubmed">33237286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar T., Narsaria U., Basak S., et al. A candidate multi-epitope vaccine against SARS-CoV-2. Scientific Reports . 2020;10(1):10895–10924. doi: 10.1038/s41598-020-67749-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-67749-1</ArticleId><ArticleId IdType="pmc">PMC7331818</ArticleId><ArticleId IdType="pubmed">32616763</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Lindestam Arlehamn C. S., Scriba T. J., et al. Development and validation of a broad scheme for prediction of HLA class II-restricted T cell epitopes. Journal of Immunological Methods . 2015;422:28–34. doi: 10.1016/j.jim.2015.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2015.03.022</ArticleId><ArticleId IdType="pmc">PMC4458426</ArticleId><ArticleId IdType="pubmed">25862607</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Sidney J., Sette A., Peters B. TepiTool: a pipeline for computational prediction of T cell epitope candidates. Current Protocols in Immunology . 2016;114(1):18.19.1–18.19.24. doi: 10.1002/cpim.12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpim.12</ArticleId><ArticleId IdType="pmc">PMC4981331</ArticleId><ArticleId IdType="pubmed">27479659</ArticleId></ArticleIdList></Reference><Reference><Citation>Vita R., Mahajan S., Overton J. A., et al. The immune epitope database (IEDB): 2018 update. Nucleic Acids Research . 2019;47(D1):339–343. doi: 10.1093/nar/gky1006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1006</ArticleId><ArticleId IdType="pmc">PMC6324067</ArticleId><ArticleId IdType="pubmed">30357391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundegaard C., Lund O., Nielsen M. Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics . 2008;24(11):1397–1398. doi: 10.1093/bioinformatics/btn128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btn128</ArticleId><ArticleId IdType="pubmed">18413329</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynisson B., Alvarez B., Paul S., Peters B., Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Research . 2020;48(W1):449–454. doi: 10.1093/nar/gkaa379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa379</ArticleId><ArticleId IdType="pmc">PMC7319546</ArticleId><ArticleId IdType="pubmed">32406916</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcinkaya B. Immunoinformatic design and evaluation of a novel multi-epitope peptide vaccine targeting SARS-CoV-2 structural and nonstructural antigens. 2021.  
 https://github.com/berkyalcinkaya/Computational-SARS-CoV-2-Vaccine-Design
.</Citation></Reference><Reference><Citation>Larsen J. E., Lund O., Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Research . 2006;2(1):p. 2. doi: 10.1186/1745-7580-2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-7580-2-2</ArticleId><ArticleId IdType="pmc">PMC1479323</ArticleId><ArticleId IdType="pubmed">16635264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponomarenko J. V., Van Regenmortel M. H. B cell epitope prediction. Structural bioinformatics . 2009;2:849–879.</Citation></Reference><Reference><Citation>Chen J., Liu H., Yang J., Chou K.-C. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids . 2007;33(3):423–428. doi: 10.1007/s00726-006-0485-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-006-0485-9</ArticleId><ArticleId IdType="pubmed">17252308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleri W., Paul S., Dhanda S. K., et al. The immune epitope database and analysis resource in epitope discovery and synthetic vaccine design. Frontiers in Immunology . 2017;8 doi: 10.3389/fimmu.2017.00278.250318</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00278</ArticleId><ArticleId IdType="pmc">PMC5348633</ArticleId><ArticleId IdType="pubmed">28352270</ArticleId></ArticleIdList></Reference><Reference><Citation>Stecher G., Tamura K., Kumar S. Molecular evolutionary genetics analysis (MEGA) for macOS. Molecular Biology and Evolution . 2020;37(4):1237–1239. doi: 10.1093/molbev/msz312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msz312</ArticleId><ArticleId IdType="pmc">PMC7086165</ArticleId><ArticleId IdType="pubmed">31904846</ArticleId></ArticleIdList></Reference><Reference><Citation>Calis J. J., Maybeno M., Greenbaum J. A., et al. Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Computational Biology . 2013;9(10) doi: 10.1371/journal.pcbi.1003266.e1003266</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1003266</ArticleId><ArticleId IdType="pmc">PMC3808449</ArticleId><ArticleId IdType="pubmed">24204222</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker J. M. The Proteomics Protocols Handbook . Berlin, Germany: Springer; 2005.</Citation></Reference><Reference><Citation>Lamiable A., Thévenet P., Rey J., Vavrusa M., Derreumaux P., Tufféry P. PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex. Nucleic Acids Research . 2016;44(W1):W449–W454. doi: 10.1093/nar/gkw329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw329</ArticleId><ArticleId IdType="pmc">PMC4987898</ArticleId><ArticleId IdType="pubmed">27131374</ArticleId></ArticleIdList></Reference><Reference><Citation>Burley S. K., Bhikadiya C., Bi C., et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering, and energy sciences. Nucleic Acids Research . 2021;49(D1):D437–D451. doi: 10.1093/nar/gkaa1038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa1038</ArticleId><ArticleId IdType="pmc">PMC7779003</ArticleId><ArticleId IdType="pubmed">33211854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitencourt-Ferreira G., Pintro V. O., de Azevedo W. F. Docking with autodock4. Methods in Molecular Biology . 2019;2053:125–148. doi: 10.1007/978-1-4939-9752-7_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9752-7_9</ArticleId><ArticleId IdType="pubmed">31452103</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Yan R., Roy A., Xu D., Poisson J., Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nature Methods . 2015;12(1):7–8. doi: 10.1038/nmeth.3213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3213</ArticleId><ArticleId IdType="pmc">PMC4428668</ArticleId><ArticleId IdType="pubmed">25549265</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson M. J., Tirado-Rives J., Jorgensen W. L. Improved peptide and protein torsional energetics with the OPLS-AA force field. Journal of Chemical Theory and Computation . 2015;11(7):3499–3509. doi: 10.1021/acs.jctc.5b00356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.5b00356</ArticleId><ArticleId IdType="pmc">PMC4504185</ArticleId><ArticleId IdType="pubmed">26190950</ArticleId></ArticleIdList></Reference><Reference><Citation>Desta I. T., Porter K. A., Xia B., Kozakov D., Vajda S. Performance and its limits in rigid-body protein-protein docking. Structure . 2020;28(9):1071–1081. e3. doi: 10.1016/j.str.2020.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7484347</ArticleId><ArticleId IdType="pubmed">32649857</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrodinger L. L. C. The PyMOL Molecular Graphics System . New York, NY, USA: Schrödinger; 2015.</Citation></Reference><Reference><Citation>Feig M. Local protein structure refinement via molecular dynamics simulations with locPREFMD. Journal of Chemical Information and Modeling . 2016;56(7):1304–1312. doi: 10.1021/acs.jcim.6b00222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.6b00222</ArticleId><ArticleId IdType="pmc">PMC4962792</ArticleId><ArticleId IdType="pubmed">27380201</ArticleId></ArticleIdList></Reference><Reference><Citation>Doytchinova I. A., Flower D. R. VaxiJen: a server for prediction of protective antigens, tumor antigens, and subunit vaccines. BMC Bioinformatics . 2007;8(1):1–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780059</ArticleId><ArticleId IdType="pubmed">17207271</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov I., Bangov I., Flower D. R., Doytchinova I. AllerTOP v. 2—a server for in silico prediction of allergens. Journal of Molecular Modeling . 2014;20(6):2278–2286. doi: 10.1007/s00894-014-2278-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00894-014-2278-5</ArticleId><ArticleId IdType="pubmed">24878803</ArticleId></ArticleIdList></Reference><Reference><Citation>Bui H.-H., Sidney J., Dinh K., Southwood S., Newman M. J., Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics . 2006;7:153–155. doi: 10.1186/1471-2105-7-153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-7-153</ArticleId><ArticleId IdType="pmc">PMC1513259</ArticleId><ArticleId IdType="pubmed">16545123</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiglione F., Deb D., Srivastava A. P., Liò P., Liso A. From infection to immunity: understanding the response to SARS-CoV2 through in-silico modeling. Frontiers in Immunology . 2021;12:646972–647049. doi: 10.3389/fimmu.2021.646972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.646972</ArticleId><ArticleId IdType="pmc">PMC8453017</ArticleId><ArticleId IdType="pubmed">34557181</ArticleId></ArticleIdList></Reference><Reference><Citation>Castiglione F., Mantile F., De Berardinis P., Prisco A. How the interval between prime and boost injection affects the immune response in a computational model of the immune system. Computational and Mathematical Methods in Medicine . 2012;2012:9. doi: 10.1155/2012/842329.842329</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/842329</ArticleId><ArticleId IdType="pmc">PMC3446774</ArticleId><ArticleId IdType="pubmed">22997539</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul S., Weiskopf D., Angelo M. A., Sidney J., Peters B., Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity. The Journal of Immunology . 2013;191(12):5831–5839. doi: 10.4049/jimmunol.1302101.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302101</ArticleId><ArticleId IdType="pmc">PMC3872965</ArticleId><ArticleId IdType="pubmed">24190657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponomarenko J., Bui H.-H., Li W., et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics . 2008;9:514–518. doi: 10.1186/1471-2105-9-514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-9-514</ArticleId><ArticleId IdType="pmc">PMC2607291</ArticleId><ArticleId IdType="pubmed">19055730</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W., Zhang C., Li Y., Pearce R., Bell E. W., Zhang Y. Folding non-homologous proteins by coupling deep-learning contact maps with I-TASSER assembly simulations. Cell reports methods . 2021;1(3) doi: 10.1016/j.crmeth.2021.100014.100014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmeth.2021.100014</ArticleId><ArticleId IdType="pmc">PMC8336924</ArticleId><ArticleId IdType="pubmed">34355210</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoodi S., Amirzakaria J. Z., Ghasemian A. In silico design and validation of a novel multi-epitope vaccine candidate against structural proteins of Chikungunya virus using comprehensive immunoinformatics analyses. PLoS One . 2023;18(5) doi: 10.1371/journal.pone.0285177.e0285177</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0285177</ArticleId><ArticleId IdType="pmc">PMC10162528</ArticleId><ArticleId IdType="pubmed">37146081</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlandini von Niessen A. G., Poleganov M. A., Rechner C., et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3′ UTRs identified by cellular library screening. Molecular Therapy . 2019;27(4):824–836. doi: 10.1016/j.ymthe.2018.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2018.12.011</ArticleId><ArticleId IdType="pmc">PMC6453560</ArticleId><ArticleId IdType="pubmed">30638957</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U., Muik A., Derhovanessian E., et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature . 2020;586(7830):594–599. doi: 10.1038/s41586-020-2814-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo C., Li X., Wu Q., et al. SARS-CoV-2 mRNA vaccine requires signal peptide to induce antibody responses. Vaccine . 2023;41(46):6863–6869. doi: 10.1016/j.vaccine.2023.09.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.09.059</ArticleId><ArticleId IdType="pubmed">37821314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin G., Zhang S., Zhong Y., et al. Community evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission through air. Atmospheric Environment . 2021;246 doi: 10.1016/j.atmosenv.2020.118083.118083</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atmosenv.2020.118083</ArticleId><ArticleId IdType="pmc">PMC7677092</ArticleId><ArticleId IdType="pubmed">33235537</ArticleId></ArticleIdList></Reference><Reference><Citation>Samad A., Ahammad F., Nain Z., et al. Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach. Journal of Biomolecular Structure and Dynamics . 2022;40(1):14–30. doi: 10.1080/07391102.2020.1792347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1792347</ArticleId><ArticleId IdType="pmc">PMC7441805</ArticleId><ArticleId IdType="pubmed">32677533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H. X., Lim J., Jazayeri S. D., Poppema S., Poh C. L. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomedical Journal . 2021;44(1):18–30. doi: 10.1016/j.bj.2020.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.09.005</ArticleId><ArticleId IdType="pmc">PMC7527307</ArticleId><ArticleId IdType="pubmed">33727051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jyotisha S. S., Singh S., Qureshi I. A. Multi-epitope vaccine against SARS-CoV-2 applying immunoinformatics and molecular dynamics simulation approaches. Journal of Biomolecular Structure and Dynamics . 2022;40(7):2917–2933. doi: 10.1080/07391102.2020.1844060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1844060</ArticleId><ArticleId IdType="pmc">PMC7682209</ArticleId><ArticleId IdType="pubmed">33164664</ArticleId></ArticleIdList></Reference><Reference><Citation>Safavi A., Kefayat A., Mahdevar E., Abiri A., Ghahremani F. Exploring the out-of-sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. Vaccine . 2020;38(48):7612–7628. doi: 10.1016/j.vaccine.2020.10.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.10.016</ArticleId><ArticleId IdType="pmc">PMC7546226</ArticleId><ArticleId IdType="pubmed">33082015</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M., Zhu Y., Li Y., et al. Design of a recombinant multivalent epitope vaccine based on SARS-CoV-2 and its variants in immunoinformatics approaches. Frontiers in Immunology . 2022;13 doi: 10.3389/fimmu.2022.884433.884433</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.884433</ArticleId><ArticleId IdType="pmc">PMC9120605</ArticleId><ArticleId IdType="pubmed">35603198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokman S. M., Rasheduzzaman M., Salauddin A., et al. Exploring the genomic and proteomic variations of SARS-CoV-2 spike glycoprotein: a computational biology approach. Infection, Genetics and Evolution . 2020;84 doi: 10.1016/j.meegid.2020.104389.104389</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104389</ArticleId><ArticleId IdType="pmc">PMC7266584</ArticleId><ArticleId IdType="pubmed">32502733</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecha J., Lee C.-Y., Bayer F. P., et al. Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing. Molecular and Cellular Proteomics . 2020;19(9):1503–1522. doi: 10.1074/mcp.ra120.002164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.ra120.002164</ArticleId><ArticleId IdType="pmc">PMC7780043</ArticleId><ArticleId IdType="pubmed">32591346</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Guo M., Tian X., et al. Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. Médica Sur . 2021;2(1):99–112.e7. doi: 10.1016/j.medj.2020.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2020.07.002</ArticleId><ArticleId IdType="pmc">PMC7373048</ArticleId><ArticleId IdType="pubmed">32838362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav R., Chaudhary J. K., Jain N., et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells . 2021;10(4):p. 821. doi: 10.3390/cells10040821.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10040821</ArticleId><ArticleId IdType="pmc">PMC8067447</ArticleId><ArticleId IdType="pubmed">33917481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H. Z., Tang L. L., Yu X. L., Zhou J., Chang Y. F., Wu X. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2. Infectious Diseases of Poverty . 2020;9(1) doi: 10.1186/s40249-020-00713-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00713-3</ArticleId><ArticleId IdType="pmc">PMC7395940</ArticleId><ArticleId IdType="pubmed">32741372</ArticleId></ArticleIdList></Reference><Reference><Citation>Samrat S. K., Tharappel A. M., Li Z., Li H. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Research . 2020;288 doi: 10.1016/j.virusres.2020.198141.198141</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2020.198141</ArticleId><ArticleId IdType="pmc">PMC7443330</ArticleId><ArticleId IdType="pubmed">32846196</ArticleId></ArticleIdList></Reference><Reference><Citation>Baruah V., Bose S. Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV. Journal of Medical Virology . 2020;92(5):495–500. doi: 10.1002/jmv.25698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25698</ArticleId><ArticleId IdType="pmc">PMC7166505</ArticleId><ArticleId IdType="pubmed">32022276</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham Peele K., Srihansa T., Krupanidhi S., Ayyagari V. S., Venkateswarulu T. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study. Journal of Biomolecular Structure and Dynamics . 2021;39(10):3793–3801. doi: 10.1080/07391102.2020.1770127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1770127</ArticleId><ArticleId IdType="pmc">PMC7284139</ArticleId><ArticleId IdType="pubmed">32419646</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanami S., Zandi M., Pourhossein B., et al. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach. International Journal of Biological Macromolecules . 2020;164:871–883. doi: 10.1016/j.ijbiomac.2020.07.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.07.117</ArticleId><ArticleId IdType="pmc">PMC7362859</ArticleId><ArticleId IdType="pubmed">32682041</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Khan T., Ali S., et al. SARS-CoV-2 new variants: characteristic features and impact on the efficacy of different vaccines. Biomedicine and Pharmacotherapy . 2021;143 doi: 10.1016/j.biopha.2021.112176.112176</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112176</ArticleId><ArticleId IdType="pmc">PMC8433040</ArticleId><ArticleId IdType="pubmed">34562770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Zhou X., Wang M., Chen X. The impact of SARS-CoV-2 on the human immune system and microbiome. Infectious Microbes and Diseases . 2021;3(1):14–21. doi: 10.1097/im9.0000000000000045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/im9.0000000000000045</ArticleId><ArticleId IdType="pmc">PMC8011344</ArticleId><ArticleId IdType="pubmed">38630064</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai J., Cai Y., Pang C., et al. Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1. Nature Communications . 2021;12(1):3433–3436. doi: 10.1038/s41467-021-23533-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23533-x</ArticleId><ArticleId IdType="pmc">PMC8187709</ArticleId><ArticleId IdType="pubmed">34103506</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Thakur M., Sharma L. K., Chandra K. Designing a multi-epitope peptide-based vaccine against SARS-CoV-2. Scientific Reports . 2020;10(1):16219–16312. doi: 10.1038/s41598-020-73371-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-73371-y</ArticleId><ArticleId IdType="pmc">PMC7530768</ArticleId><ArticleId IdType="pubmed">33004978</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar B., Ullah M. A., Johora F. T., Taniya M. A., Araf Y. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2) Immunobiology . 2020;225(3) doi: 10.1016/j.imbio.2020.151955.151955</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2020.151955</ArticleId><ArticleId IdType="pmc">PMC7211625</ArticleId><ArticleId IdType="pubmed">32517882</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Zayat S. R., Sibaii H., Mannaa F. A. Toll-like receptors activation, signaling, and targeting: an overview. Bulletin of the National Research Centre . 2019;43(1):187–212. doi: 10.1186/s42269-019-0227-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42269-019-0227-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Das N. C., Patra R., Gupta P. S. S., et al. Designing of a novel multi-epitope peptide-based vaccine against Brugia malayi: an in silico approach. Infection, Genetics and Evolution . 2021;87 doi: 10.1016/j.meegid.2020.104633.104633</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104633</ArticleId><ArticleId IdType="pubmed">33181335</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorai S., Das N. C., Gupta P. S. S., Panda S. K., Rana M. K., Mukherjee S. Designing efficient multi-epitope peptide-based vaccine by targeting the antioxidant thioredoxin of bancroftian filarial parasite. Infection, Genetics and Evolution . 2022;98 doi: 10.1016/j.meegid.2022.105237.105237</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2022.105237</ArticleId><ArticleId IdType="pubmed">35131521</ArticleId></ArticleIdList></Reference><Reference><Citation>Das N. C., Gupta P. S. S., Panda S. K., Rana M. K., Mukherjee S. Reverse vaccinology assisted design of a novel multi-epitope vaccine to target Wuchereria bancrofti cystatin: an immunoinformatics approach. International Immunopharmacology . 2023;115 doi: 10.1016/j.intimp.2022.109639.109639</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109639</ArticleId><ArticleId IdType="pubmed">36586276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S. J., Shin S. J., Lee M. H., et al. A potential protein adjuvant derived from Mycobacterium tuberculosis Rv0652 enhances dendritic cells-based tumor immunotherapy. PLoS One . 2014;9(8) doi: 10.1371/journal.pone.0104351.e104351</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0104351</ArticleId><ArticleId IdType="pmc">PMC4125215</ArticleId><ArticleId IdType="pubmed">25102137</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra K. K., Mishra A. K., Anand V., Pandey A., Budhwar S., Sharma D. C. Design of a multi-epitope vaccine against covid-19: an in silico approach. Current Biotechnology . 2023;12(3):151–168. doi: 10.2174/2211550112666230612153430.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/2211550112666230612153430</ArticleId></ArticleIdList></Reference><Reference><Citation>Tourani M., Samavarchi Tehrani S., Movahedpour A., et al. Design and evaluation of a multi-epitope vaccine for COVID-19: an in silico approach. Health Science Monitor . 2023;2(3):180–204. doi: 10.61186/hsm.2.3.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.61186/hsm.2.3.180</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi A., Chaitanya N. S. In silico, designing of multi-epitope vaccine construct against human coronavirus infections. Journal of Biomolecular Structure and Dynamics . 2021;39(18):6903–6917. doi: 10.1080/07391102.2020.1804460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1804460</ArticleId><ArticleId IdType="pmc">PMC7484569</ArticleId><ArticleId IdType="pubmed">32772892</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh M., Amini-Khoei H., Tahmasebian S., et al. Designing a novel multi-epitope vaccine against Ebola virus using reverse vaccinology approach. Scientific Reports . 2022;12(1):p. 7757. doi: 10.1038/s41598-022-11851-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11851-z</ArticleId><ArticleId IdType="pmc">PMC9094136</ArticleId><ArticleId IdType="pubmed">35545650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojha R., Singh S., Gupta N., Kumar K., Padhi A. K., Prajapati V. K. Multi-pathogen-based chimeric vaccine to fight against COVID-19 and concomitant coinfections. Biotechnology Letters . 2023;45(7):779–797. doi: 10.1007/s10529-023-03380-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10529-023-03380-0</ArticleId><ArticleId IdType="pmc">PMC10163573</ArticleId><ArticleId IdType="pubmed">37148345</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin W. R., Cheng F. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein. Journal of Biomolecular Structure and Dynamics . 2022;40(15):7099–7113. doi: 10.1080/07391102.2021.1894986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2021.1894986</ArticleId><ArticleId IdType="pmc">PMC9003619</ArticleId><ArticleId IdType="pubmed">33715598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Rathi E., Kini S. G. Computational design of a broad-spectrum multi-epitope vaccine candidate against seven strains of human coronaviruses. 3 Biotech . 2022;12(9):p. 240. doi: 10.1007/s13205-022-03286-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13205-022-03286-0</ArticleId><ArticleId IdType="pmc">PMC9395775</ArticleId><ArticleId IdType="pubmed">36003896</ArticleId></ArticleIdList></Reference><Reference><Citation>Maleki A., Russo G., Parasiliti Palumbo G. A., Pappalardo F. In silico design of recombinant multi-epitope vaccine against influenza A virus. BMC Bioinformatics . 2021;22(14):p. 617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8808469</ArticleId><ArticleId IdType="pubmed">35109785</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Kemp S. A., Papa G., et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7. Cell Reports . 2021;35(13) doi: 10.1016/j.celrep.2021.109292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId><ArticleId IdType="pmc">PMC8185188</ArticleId><ArticleId IdType="pubmed">34166617</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C., Toyoda M., Zahradnik J., et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host &amp; Microbe . 2021;29(7):1124–1136. e11. doi: 10.1016/j.chom.2021.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.006</ArticleId><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistry P., Barmania F., Mellet J., et al. SARS-CoV-2 variants, vaccines, and host immunity. Frontiers in Immunology . 2021;12 doi: 10.3389/fimmu.2021.809244.809244</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.809244</ArticleId><ArticleId IdType="pmc">PMC8761766</ArticleId><ArticleId IdType="pubmed">35046961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X., Li J. J., Liu T., Brian O., Li J. Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. Briefings in Functional Genomics . 2021;20(5):289–303. doi: 10.1093/bfgp/elab027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bfgp/elab027</ArticleId><ArticleId IdType="pmc">PMC8194884</ArticleId><ArticleId IdType="pubmed">34089044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan M. J., Lyke K. E., Kitchin N., et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature . 2020;586(7830):589–593. doi: 10.1038/s41586-020-2639-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2639-4</ArticleId><ArticleId IdType="pubmed">32785213</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E. E., Frenck R. W., Falsey A. R., et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New England Journal of Medicine . 2020;383(25):2439–2450. doi: 10.1056/nejmoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett K. S., Flynn B., Foulds K. E., et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine . 2020;383(16):1544–1555. doi: 10.1056/nejmoa2024671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa2024671</ArticleId><ArticleId IdType="pmc">PMC7449230</ArticleId><ArticleId IdType="pubmed">32722908</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C., Haefner E., Gerbeth J., et al. A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections. Molecular Therapy - Nucleic Acids . 2022;28:743–754. doi: 10.1016/j.omtn.2022.04.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2022.04.036</ArticleId><ArticleId IdType="pmc">PMC9126847</ArticleId><ArticleId IdType="pubmed">35664702</ArticleId></ArticleIdList></Reference><Reference><Citation>Beissert T., Perkovic M., Vogel A., et al. A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Molecular Therapy . 2020;28(1):119–128. doi: 10.1016/j.ymthe.2019.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.09.009</ArticleId><ArticleId IdType="pmc">PMC6953774</ArticleId><ArticleId IdType="pubmed">31624015</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y., Dai T., Wei Y., Zhang L., Zheng M., Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction and Targeted Therapy . 2020;5(1):p. 237. doi: 10.1038/s41392-020-00352-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00352-y</ArticleId><ArticleId IdType="pmc">PMC7551521</ArticleId><ArticleId IdType="pubmed">33051445</ArticleId></ArticleIdList></Reference><Reference><Citation>Poh C. M., Carissimo G., Wang B., et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nature Communications . 2020;11(1):p. 2806. doi: 10.1038/s41467-020-16638-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16638-2</ArticleId><ArticleId IdType="pmc">PMC7264175</ArticleId><ArticleId IdType="pubmed">32483236</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith C. C., Olsen K. S., Gentry K. M., et al. Landscape and selection of vaccine epitopes in SARS-CoV-2. Genome Medicine . 2021;13(1):p. 101. doi: 10.1186/s13073-021-00910-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-021-00910-1</ArticleId><ArticleId IdType="pmc">PMC8201469</ArticleId><ArticleId IdType="pubmed">34127050</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Ma M.-l, Lei Q., et al. Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients. Cell Reports . 2021;34(13) doi: 10.1016/j.celrep.2021.108915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108915</ArticleId><ArticleId IdType="pmc">PMC7953450</ArticleId><ArticleId IdType="pubmed">33761319</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirakhoo F., Kuo L., Peng J., et al.  A Novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an AAV hACE2 mouse model and non-human primates. 2020.  
 https://www.biorxiv.org/content/10.1101/2020.11.30.399154v2
.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.11.30.399154v2</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarmarkovich M., Warrington J. M., Farrel A., Maris J. M. Identification of SARS-CoV-2 vaccine epitopes predicted to induce long-term population-scale immunity. Cell Reports Medicine. . 2020;1(3) doi: 10.1016/j.xcrm.2020.100036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2020.100036</ArticleId><ArticleId IdType="pmc">PMC7276303</ArticleId><ArticleId IdType="pubmed">32835302</ArticleId></ArticleIdList></Reference><Reference><Citation>Nafian F., Nafian S., Kamali Doust Azad B. Regulatory and biosafety challenges for vaccines. Iranian Journal of Medical Microbiology . 2020;14(1):17–29. doi: 10.30699/ijmm.14.1.17.</Citation><ArticleIdList><ArticleId IdType="doi">10.30699/ijmm.14.1.17</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>